Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$43.01
3.809.69%
At close: -
$42.75
-0.26-0.60%
After Hours: Jun 6, 6:45 PM EDT
Comments
Loading...
Sarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | Benzinga
Sarepta Therapeutics Inc has a consensus price target of $133.89 based on the ratings of 27 analysts. The high is $230 issued by Leerink Partners on June 24, 2024. The low is $40 issued by HC Wainwright & Co. on May 22, 2025. The 3 most-recent analyst ratings were released by Scotiabank, HC Wainwright & Co., and JP Morgan on June 6, 2025, May 22, 2025, and May 20, 2025, respectively. With an average price target of $68 between Scotiabank, HC Wainwright & Co., and JP Morgan, there's an implied 59.06% upside for Sarepta Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
HC Wainwright & Co.
JP Morgan
Wells Fargo
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Sarepta Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/06/2025 | Buy Now | 87.13% | Scotiabank | Louise Chen56% | $80 → $80 | Upgrade | Sector Perform → Sector Outperform | Get Alert |
| 05/22/2025 | Buy Now | -6.43% | HC Wainwright & Co. | Raghuram Selvaraju44% | $40 → $40 | Reiterates | Neutral → Neutral | Get Alert |
| 05/20/2025 | Buy Now | 96.49% | JP Morgan | Anupam Rama59% | $169 → $84 | Maintains | Overweight | Get Alert |
| 05/08/2025 | Buy Now | 133.92% | Wells Fargo | Yanan Zhu43% | $115 → $100 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 35.67% | RBC Capital | Brian Abrahams50% | $87 → $58 | Maintains | Sector Perform | Get Alert |
| 05/07/2025 | Buy Now | 133.92% | Goldman Sachs | Salveen Richter53% | $178 → $100 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 129.24% | Guggenheim | Debjit Chattopadhyay54% | $112 → $98 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 63.74% | Piper Sandler | Biren Amin40% | $110 → $70 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 187.72% | Oppenheimer | Hartaj Singh45% | $184 → $123 | Maintains | Outperform | Get Alert |
| 05/07/2025 | Buy Now | 89.47% | Cantor Fitzgerald | Kristen Kluska71% | $163 → $81 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | -6.43% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $40 | Maintains | Neutral | Get Alert |
| 05/07/2025 | Buy Now | 164.33% | Morgan Stanley | Matthew Harrison61% | $182 → $113 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 192.4% | Needham | Gil Blum52% | $183 → $125 | Maintains | Buy | Get Alert |
| 04/21/2025 | Buy Now | 157.31% | Piper Sandler | Biren Amin40% | $182 → $110 | Maintains | Overweight | Get Alert |
| 04/16/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Neutral → Neutral | Get Alert |
| 04/11/2025 | Buy Now | 325.73% | Morgan Stanley | Matthew Harrison61% | $196 → $182 | Maintains | Overweight | Get Alert |
| 04/11/2025 | Buy Now | 169.01% | Wells Fargo | Yanan Zhu43% | → $115 | Initiates | → Overweight | Get Alert |
| 04/07/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Neutral → Neutral | Get Alert |
| 04/04/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Neutral → Neutral | Get Alert |
| 04/03/2025 | Buy Now | 328.07% | Needham | Gil Blum52% | $202 → $183 | Maintains | Buy | Get Alert |
| 04/02/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Upgrade | Sell → Neutral | Get Alert |
| 03/31/2025 | Buy Now | 103.51% | RBC Capital | Brian Abrahams50% | $161 → $87 | Downgrade | Outperform → Sector Perform | Get Alert |
| 03/20/2025 | Buy Now | 87.13% | Scotiabank | Louise Chen56% | $105 → $80 | Maintains | Sector Perform | Get Alert |
| 03/19/2025 | Buy Now | 281.29% | Cantor Fitzgerald | Kristen Kluska71% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 03/19/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 03/19/2025 | Buy Now | 131.58% | Deutsche Bank | David Hoang41% | $124 → $99 | Maintains | Hold | Get Alert |
| 03/18/2025 | Buy Now | 372.51% | Needham | Gil Blum52% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | 281.29% | Cantor Fitzgerald | Kristen Kluska71% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 145.61% | Scotiabank | Louise Chen56% | → $105 | Initiates | → Sector Perform | Get Alert |
| 02/27/2025 | Buy Now | 276.61% | RBC Capital | Brian Abrahams50% | $165 → $161 | Maintains | Outperform | Get Alert |
| 02/27/2025 | Buy Now | 372.51% | Needham | Gil Blum52% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 02/13/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/30/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Raghuram Selvaraju44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/27/2025 | Buy Now | 372.51% | Needham | Gil Blum52% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/14/2025 | Buy Now | 372.51% | Needham | Gil Blum52% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 12/03/2024 | Buy Now | 75.44% | HC Wainwright & Co. | Mitchell Kapoor44% | $80 → $75 | Maintains | Sell | Get Alert |
| 11/27/2024 | Buy Now | 325.73% | Piper Sandler | Biren Amin40% | $200 → $182 | Maintains | Overweight | Get Alert |
| 11/27/2024 | Buy Now | 372.51% | Needham | Gil Blum52% | $205 → $202 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 87.13% | HC Wainwright & Co. | Mitchell Kapoor44% | → $80 | Initiates | → Sell | Get Alert |
| 11/07/2024 | Buy Now | 250.88% | Guggenheim | Whitney Ijem57% | $148 → $150 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 351.46% | Baird | Brian Skorney58% | $200 → $193 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 290.64% | Cantor Fitzgerald | Kristen Kluska71% | $152 → $167 | Upgrade | Neutral → Overweight | Get Alert |
| 11/07/2024 | Buy Now | 297.66% | Evercore ISI Group | Gavin Clark-Gartner39% | $179 → $170 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 379.53% | Needham | Gil Blum52% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | 325.73% | RBC Capital | Brian Abrahams50% | $182 → $182 | Reiterates | Outperform → Outperform | Get Alert |
| 10/21/2024 | Buy Now | 285.96% | Jefferies | Andrew Tsai25% | → $165 | Initiates | → Buy | Get Alert |
| 10/14/2024 | Buy Now | 379.53% | Needham | Gil Blum52% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2024 | Buy Now | 250.88% | Raymond James | Danielle Brill44% | → $150 | Reinstates | → Outperform | Get Alert |
| 10/04/2024 | Buy Now | 325.73% | RBC Capital | Brian Abrahams50% | $181 → $182 | Maintains | Outperform | Get Alert |
| 09/20/2024 | Buy Now | 255.56% | Cantor Fitzgerald | Kristen Kluska71% | $152 → $152 | Reiterates | Neutral → Neutral | Get Alert |
| 09/19/2024 | Buy Now | 323.39% | RBC Capital | Brian Abrahams50% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 09/06/2024 | Buy Now | 323.39% | RBC Capital | Brian Abrahams50% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 323.39% | RBC Capital | Brian Abrahams50% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2024 | Buy Now | 323.39% | RBC Capital | Brian Abrahams50% | $182 → $181 | Maintains | Outperform | Get Alert |
| 08/08/2024 | Buy Now | 274.27% | Citigroup | David Hoang41% | $176 → $160 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 255.56% | Cantor Fitzgerald | Kristen Kluska71% | $167 → $152 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 367.84% | Piper Sandler | Biren Amin40% | $205 → $200 | Maintains | Overweight | Get Alert |
| 08/08/2024 | Buy Now | 318.71% | Evercore ISI Group | Gavin Clark-Gartner39% | $185 → $179 | Upgrade | In-Line → Outperform | Get Alert |
| 08/08/2024 | Buy Now | 374.85% | Barclays | Gena Wang62% | $226 → $203 | Maintains | Overweight | Get Alert |
| 07/29/2024 | Buy Now | 325.73% | RBC Capital | Brian Abrahams50% | → $182 | Upgrade | Sector Perform → Outperform | Get Alert |
| 07/01/2024 | Buy Now | 379.53% | Piper Sandler | Biren Amin40% | $205 → $205 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 449.71% | Needham | Gil Blum52% | $235 → $235 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 311.7% | Citigroup | David Hoang41% | $172 → $176 | Downgrade | Buy → Neutral | Get Alert |
| 06/24/2024 | Buy Now | 367.84% | Morgan Stanley | Matthew Harrison61% | $165 → $200 | Maintains | Overweight | Get Alert |
| 06/24/2024 | Buy Now | 332.75% | Evercore ISI Group | Gavin Clark-Gartner39% | $139 → $185 | Maintains | In-Line | Get Alert |
| 06/24/2024 | Buy Now | 367.84% | BMO Capital | Kostas Biliouris35% | $170 → $200 | Maintains | Outperform | Get Alert |
| 06/24/2024 | Buy Now | 438.01% | Leerink Partners | Mani Foroohar47% | $165 → $230 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 285.96% | Morgan Stanley | Matthew Harrison61% | $165 → $165 | Reiterates | Overweight → Overweight | Get Alert |
| 06/21/2024 | Buy Now | 267.25% | Piper Sandler | Biren Amin40% | $157 → $157 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | 199.42% | Cantor Fitzgerald | Kristen Kluska71% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 06/21/2024 | Buy Now | 325.73% | RBC Capital | Brian Abrahams50% | $142 → $182 | Maintains | Sector Perform | Get Alert |
| 06/21/2024 | Buy Now | 428.65% | Barclays | Gena Wang62% | $185 → $226 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | 367.84% | Baird | Brian Skorney58% | $170 → $200 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 398.25% | B of A Securities | Tazeen Ahmad55% | $166 → $213 | Maintains | Buy | Get Alert |
| 06/21/2024 | Buy Now | 449.71% | Needham | Gil Blum52% | $166 → $235 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 297.66% | BMO Capital | Kostas Biliouris35% | $170 → $170 | Maintains | Outperform | Get Alert |
| 06/14/2024 | Buy Now | 297.66% | BMO Capital | Kostas Biliouris35% | $170 → $170 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | 267.25% | Piper Sandler | Biren Amin40% | → $157 | Initiates | → Overweight | Get Alert |
| 05/28/2024 | Buy Now | 232.16% | RBC Capital | Brian Abrahams50% | $157 → $142 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/20/2024 | Buy Now | 288.3% | Needham | Gil Blum52% | $166 → $166 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2024 | Buy Now | 318.71% | Mizuho | Uy Ear61% | $145 → $179 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 321.05% | Oppenheimer | Hartaj Singh45% | → $180 | Upgrade | Perform → Outperform | Get Alert |
| 05/03/2024 | Buy Now | 309.36% | JP Morgan | Anupam Rama59% | $177 → $175 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 288.3% | Needham | Gil Blum52% | $166 → $166 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 199.42% | Cantor Fitzgerald | Kristen Kluska71% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 03/01/2024 | Buy Now | 290.64% | UBS | Colin Bristow39% | $164 → $167 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 199.42% | Cantor Fitzgerald | Kristen Kluska71% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/29/2024 | Buy Now | 267.25% | RBC Capital | Brian Abrahams50% | $151 → $157 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 302.34% | Citigroup | David Hoang41% | $160 → $172 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 332.75% | Barclays | Gena Wang62% | $141 → $185 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 288.3% | Needham | Gil Blum52% | $169 → $166 | Maintains | Buy | Get Alert |
| 02/20/2024 | Buy Now | 423.98% | Wedbush | Andreas Argyrides71% | $224 → $224 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 222.81% | Evercore ISI Group | Gavin Clark-Gartner39% | $108 → $138 | Maintains | In-Line | Get Alert |
| 02/16/2024 | Buy Now | 295.32% | Needham | Gil Blum52% | $140 → $169 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | 199.42% | Cantor Fitzgerald | Kristen Kluska71% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/14/2024 | Buy Now | 199.42% | Cantor Fitzgerald | Kristen Kluska71% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 02/14/2024 | Buy Now | 239.18% | Mizuho | Uy Ear61% | $130 → $145 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Sarepta Therapeutics (SRPT) stock?
The latest price target for Sarepta Therapeutics (NASDAQ:SRPT) was reported by Scotiabank on June 6, 2025. The analyst firm set a price target for $80.00 expecting SRPT to rise to within 12 months (a possible 87.13% upside). 80 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sarepta Therapeutics (SRPT)?
The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by Scotiabank, and Sarepta Therapeutics upgraded their sector outperform rating.
When was the last upgrade for Sarepta Therapeutics (SRPT)?
The last upgrade for Sarepta Therapeutics Inc happened on June 6, 2025 when Scotiabank raised their price target to $80. Scotiabank previously had a sector perform for Sarepta Therapeutics Inc.
When was the last downgrade for Sarepta Therapeutics (SRPT)?
The last downgrade for Sarepta Therapeutics Inc happened on March 31, 2025 when RBC Capital changed their price target from $161 to $87 for Sarepta Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Sarepta Therapeutics (SRPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sarepta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sarepta Therapeutics was filed on June 6, 2025 so you should expect the next rating to be made available sometime around June 6, 2026.
Is the Analyst Rating Sarepta Therapeutics (SRPT) correct?
While ratings are subjective and will change, the latest Sarepta Therapeutics (SRPT) rating was a upgraded with a price target of $80.00 to $80.00. The current price Sarepta Therapeutics (SRPT) is trading at is $42.75, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
